Pharnext – executive interview

Pharnext – executive interview

Pharnext — 1 video in collection

More on this equity

In this interview we speak to David Solomon, CEO of Pharnext, a Euronext Paris-listed company developing medicines for neurological disorders based on its Pleotherapy platform, which unearths new therapeutic effects from drug combinations. Its lead program is PXT3003 for Charcot-Marie-Tooth disease, which is entering Phase III.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free